Gender differences in non‑pharmacological treatment of chronic heart failure

Česká verzia

Authors: A. Klabník ¹; J. Murín ²; P. Kyčina ³
Authors place of work: Kardiologické oddelenie Stredoslovenského ústavu srdcových a cievnych chorôb, a. s., Banská Bystrica, Slovenská republika, prednosta prim. MU Dr. Peter Mečiar ¹; I. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednostka doc. MU Dr. Soňa Kiňová, Ph. D. ²; Interné oddelenie Liptovskej nemocnice s poliklinikou Liptovský Mikuláš, Slovenská republika, prednosta prim. MUDr. Viliam Iľanovský ³
Published in the journal: Vnitř Lék 2010; 56(5): 427-433
Category: Reviews

Summary

Prior studies demonstrated sex‑related differences in many aspects of chronic heart failure (HF), and in the appropriate use, individual response or complication rates with non‑pharmacological treatment, too. There is seasonal variability in morbidity and mortality of HF with significant gender differences, partially due to respiratory diseases, which may be potentionally preventable by vaccination. Quitting smoking is associated with substantial decrease in morbidity and mortality in HF patients which is similar in magnitude to the effect of an appropriate beta‑blocker use. Yet little emphasis has been placed on smoking cessation strategies in women with HF and should be adopted as vigorously as proven medical therapy. Complications of catheter ablation for atrial fibrillation were more frequent in females. Gender disparity exists in the use of implantable cardioverter‑ defibrillators and cardiac resynchronization therapy, although they are beneficial for both women and men. Smaller women have limited access to left ventricular assist device (LVAD) because these devices require a minimum body surface to fit properly. Women were more likely than men to develop severe right ventricular failure after implantation of LVAD. Lower cut‑off level of peak oxygen consumption was suggested for women to determine optimal timing for heart transplantation. Disease management programs probably narrows gender differences in quality of care and survival among HF patients. Women with HF have less access to cardiologists, although this consultation is associated with better quality of care, particularly for women. Despite these known sex differences, recommendations for HF are the same for women and men, because prospective sex‑ specific clinical trials have not been performed.

Key words:
gender – sex – female – women – heart failure – smoking cessation – therapy

Zdroje

1. Konhilas JP, Leinwand LA. The effects of biological sex and diet on the development of heart failure. Circulation 2007; 116: 2747– 2759.

2. Klabník A, Murín J. Chronické srdcové zlyhávanie – zaostrené na ženy. Cor Vasa 2009; 51: 805– 812.

3. Klabník A, Murín J. Rozdiely medzi pohlaviami vo farmakoterapii chronického srdcového zlyhávania. Vnitř Lék 2009; 55: 1167– 1172.

4. Dickstein K, Cohen‑ Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388– 2442.

5. Opasich C, Febo O, Riccardi PG et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol 1996; 78: 354– 357.

6. Stewart S, McIntyre K, Capewell S et al. Heart failure in a cold climate. Seasonal variation in heart failure‑related morbidity and mortality. J Am Coll Cardiol 2002; 39: 760– 766.

7. O’Connor CM, Whellan DJ, Lee KL et al. Efficacy and safety of exercise training in patients with chronic heart failure. HF- ACTION randomized controlled trial. JAMA 2009; 301: 1439– 1450.

8. He J, Ogden LG, Bazzano LA et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow‑up study. Arch Intern Med 2001; 161: 996– 1002.

9. Fonarow GC, Abraham WT, Albert NM et al. A smoker’s paradox in patients hospitalized for heart failure: findings from OPTIMIZE- HF. Eur Heart J 2008; 29: 1983– 1991.

10. Suskin N, Sheth T, Negassa A et al. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 37: 1677– 1682.

11. Králiková E, Býma S, Cífková R et al. Doporučení pro léčbu závislosti na tabáku. Čas Lék Čes 2005; 144: 327– 333.

12. Perkins KA. Smoking cessation in women: special considerations. CNS Drugs 2001; 15: 391– 411.

13. McVary KT, Carrier S, Wessells H et al. Smoking and erectile dysfunction: evidence based analysis. J Urol 2001; 166: 1624– 1632.

14. Joseph AM, Norman SM, Ferry LH et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335: 1792– 1798.

15. Nicotine replacement therapy for patients with coronary artery disease. Working group for the study of transdermal nicotine in patients with coronary artery disease. Arch Intern Med 1994; 154: 989– 995.

16. Králiková E. Nový lék závislosti na tabáku: varenicline, parciální agonista a4b2 acetylcholin‑nikotinových receptorů. Čas Lék Čes 2006; 145: 832– 834.

17. Rigotti NA, Pipe AL, Benowitz NL et al. Efficacy and safety of vareniciline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221– 229.

18. Gerstenfeld EP, Callans D, Dixit S et al. Characteristics of patients undergoing atrial fibrillation ablation: trends over a seven‑year period 1999– 2005. J Cardiovasc Electrophysiol 2007; 18: 23– 28.

19. Spragg DD, Dalal D, Cheema A et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 2008; 19: 627– 631.

20. Russo AM, Stamato NJ, Lehmann MH et al. Influence of sex on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. J Cardiovasc Electrophysiol 2004; 15: 993– 998.

21. Kadish A, Dyer A, Daubert JP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151– 2158.

22. Zareba W, Moss AJ, Jackson HW et al. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol 2005; 16: 1265– 1270.

23. Albert CM, Quigg R, Saba S et al. DEFINITE investigators. Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy. Am Heart J 2008; 156: 367– 372.

24. Hernandez AF, Fonarow GC, Liang L et al. Sex and racial differences in the use of implantable cardioverter‑ defibrillators among patients hospitalized with heart failure. JAMA 2007; 298: 1525– 1532.

25. Peterson PN, Daugherty SL, Wang Y et al. National Cardiovascular Data Registry. Gender differences in procedure‑related adverse events in patients receiving cardioverter‑ defibrillator therapy. Circulation 2009; 119: 1078– 1084.

26. Cleland JG, Daubert JC, Erdmann E et al. Cardiac Resynchronization‑ Heart Failure (CARE‑ HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539– 1549.

27. Alaeddini J, Wood MA, Amin MS et al. Gender disparity in the use of cardiac resynchronization therapy in the United States. Pacing Clin Electrophysiol 2008; 31: 468– 472.

28. Lilli A, Ricciardi G, Porciani MC et al. Cardiac resynchronization therapy: gender related differences in left ventricular reverse remodeling. Pacing Clin Electrophysiol 2007; 30: 1349– 1355.

29. Bleeker GB, Schalij MJ, Boersma E et al. Does a gender difference in response to cardiac resynchronization therapy exist? Pacing Clin Electrophysiol 2005; 28: 1271– 1275.

30. van Bommel RJ, Bax JJ, Abraham WT et al. Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub‑analysis. Eur Heart J 2009; 30: 2470– 2477.

31. Moss AJ, Hall WJ, Cannom DS et al. MADIT‑ CRT Trial Investigators. Cardiac‑ resynchronization therapy for the prevention of heart‑ failure events. N Engl J Med 2009; 361: 1329– 1338.

32. Goncalvesová E, Hulman M, Olejárová I et al. Iniciálne skúsenosti s implantabilnými mechanickými podporami ľavej komory v programe transplantácie srdca v Národnom ústave srdcových a cievnych chorôb. Cardiol 2008; 17: 101– 108.

33. Lahpor J, Khaghani A, Hetzer R et al. European results with a continuous‑ flow ventricular assist device for advanced heart failure patients. Eur J Cardiothorac Surg 2010; 37: 357– 361.

34. Joyce DL, Conte JV, Russell SD et al. Disparities in access to left ventricular assist device therapy. J Surg Res 2009; 152: 111– 117.

35. Bogaev RC, Chen L, Russell SD et al. An emerging option for women with advanced heart failure: results of the HeartMate II continuous flow left ventricular assist device bridge to transplant trial. Circulation 2007; 116: 1372. Abstract 1762.

36. Ochiai Y, McCarthy PM, Smedira NG. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation 2002; 106 (12 Suppl 1): 1198– 1202.

37. Aaronson KD, Schwartz JS, Goin JE et al. Sex differences in patient acceptance of cardiac transplantation candidacy. Circulation 1995; 91: 2753– 2761.

38. Crandall BG, Renland DG, O‘Connell JB et al. Increased frequency of cardiac allograft rejection in female heart transplant recipients. J Heart Lung Transplant 1988; 7: 419– 423.

39. Wechsler ME, Giardina EV, Sciacca RR et al. Increased early mortality in women undergoing cardiac transplantation. Circulation 1995; 91: 1029– 1035.

40. Elmariah S, Goldberg LR, Allen MT et al. Effects of gender on peak oxygen consumption and the timing of cardiac transplantation. J Am Coll Cardiol 2006; 47: 2237– 2242.

41. Niederle P. Zlepšení v přístupu k ambulantní léčbě chronického srdečního selhání. Ambulance a jednotky srdečního selhání. Cardiol 2006; 15: 134– 139.

42. Gattis WA, Hasselblad V, Whellan DJ et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Arch Intern Med 1999; 159: 1939– 1945.

43. Bero LA, Grilli R, Grimshaw JM et al. Getting research findings into practice. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 1998; 317: 465– 468.

44. Jong P, Gong Y, Liu PP et al. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared to other specialists. Circulation 2003; 108: 184– 191.

45. Cook NL, Ayanian JZ, Orav EJ et al. Differences in specialist consultations for cardiovascular disease by race, ethnicity, gender, insurance status, and site of primary care. Circulation 2009; 119: 2463– 2470.

46. Arcement LM, Horswell R, Singh M et al. Disease management reduces racial and gender differences in survival among indigent patients with systolic heart failure. Chest (Abstracts) 2007; 132: 580c– 581c.

47. Houston‑ Feenstra L, Chiong J, Jutzy K. Gender comparison of outcomes 48 months following a disease management and rehabilitation program for patients with congestive heart failure and patients followed by routine care for CHF. Chest (Abstracts) 2008; 134: p41001.

48. Yancy CW, Fonarow GC, Albert NM et al. Influence of patient age and sex on delivery of guideline‑ recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J 2009; 157: 754– 762.

49. Fonarow GC, Abraham WT, Albert NM et al. Age‑ and gender‑related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE‑ HF). Am J Cardiol 2009; 104: 107– 115.

50. Goldberg RJ, Goldberg JH, Pruell S et al. Delays in seeking medical care in hospitalized patients with decompensated heart failure. Am J Med 2008; 121: 212– 218.

51. Nieminen MS, Harjola VP, Hochadel M et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail 2008; 10: 140– 148.

52. Roe CM, Motheral BR, Teitelbaum F et al. Angiotensin‑converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J 1999; 138: 818– 825.